What is Gelteq?
Headquartered in Australia, Gelteq specializes in the sophisticated transformation of traditional oral compounds into advanced, edible gel formats. This innovative delivery mechanism is engineered to enhance the bioavailability, absorption rates, and overall ease of consumption for a diverse range of applications, including pharmaceuticals, nutraceuticals, animal health, and sports nutrition. By offering comprehensive services that span formulation, development, manufacturing, and licensing, the company provides a versatile platform for partners looking to modernize their drug and nutrient administration strategies. Gelteq's technology addresses the persistent challenge of patient compliance and product efficacy, effectively bridging the gap between complex chemical formulations and user-friendly delivery systems.
How much funding has Gelteq raised?
Gelteq has raised a total of $3.5M across 1 funding round:
Debt
$3.5M
Debt (2026): $3.5M, investors not publicly disclosed
Key Investors in Gelteq
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Gelteq?
With this major enterprise-level funding, Gelteq is poised to accelerate its operational scaling and expand its licensing footprint across international markets. The strategic deployment of this capital will likely focus on increasing manufacturing capacity to meet the growing demand for alternative delivery technologies. Furthermore, the company is expected to deepen its research and development efforts, potentially broadening its intellectual property portfolio to include specialized applications for high-growth sectors such as personalized medicine and advanced veterinary care. As the healthcare industry continues to prioritize patient-centric solutions, Gelteq's platform is well-positioned to become a standard-bearer for next-generation oral delivery, driving long-term value for its stakeholders and partners alike.
See full Gelteq company page
